化学
共价键
效力
共价结合
药理学
结构-活动关系
癌症
癌症研究
生物化学
IC50型
体外
抗药性
组合化学
细胞生长
细胞培养
癌细胞
小分子
生物活性
后天抵抗
酶抑制剂
化学合成
作者
Wenjian Zhu,Jing Guo,颜玲,Xiaojing Lin,Xiaojuan Chen,Xiaojuan Song,Wuqing Deng,Yixin Luo,Zhengchao Tu,Yongheng Chen,Jeff Bruce Smaill,Adam Vorn Patterson,Xiaoyun Lu
标识
DOI:10.1021/acs.jmedchem.6c02574
摘要
Abstract Oncogenic FGFR alterations drive the development of multiple cancers. However, acquired resistance to clinically approved inhibitors mediated by gatekeeper and molecular brake mutations poses a major therapeutic challenge. Herein, we describe the structure-based discovery of (Z)-3-(amino(phenyl)methylene)indolin-2-one derivatives as potent covalent pan-FGFR inhibitors. The representative compound, 9v, displayed high potency against FGFR1/2/3/4 (IC50 = 8.6, 5.4, 4.4, and 6.9 nM, respectively) and potent antiproliferative effects across a panel of FGFR-driven cancer cell lines (IC50 = 0.3−6.1 nM). Notably, 9v retained high efficacy against common resistance mutations, including the gatekeeper (FGFR1 V561M, FGFR2 V564F, and FGFR3 V555M) and “molecular brake” (FGFR2 N549K) variants, with IC50 values of <0.1 nM. Covalent modification of FGFR3 by 9v was confirmed through MALDI-TOF-MS and LC−MS/MS-based site mapping. Furthermore, 9v exhibited significant antitumor efficacy in an RT112/84 bladder cancer xenograft model, providing a promising strategy to overcome resistance in FGFR-targeted therapy.
科研通智能强力驱动
Strongly Powered by AbleSci AI